Bcl-2 protein and DNA ploidy in renal cell carcinoma: Do they affect patient prognosis?

International Journal of Urology

Volumn 12, Issue 6, 2005, Pages 563-569

  Skolarikos, Andreas ^a,b   Alivizatos, Gerasimos ^a   Bamias, Aristotelis ^a   Mitropoulos, Dionysios ^a   Ferakis, Nikolaos ^a   Deliveliotis, Charalampos ^a   Dimopoulos, Meletios Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Bcl 2; DNA ploidy; Prognosis; Renal cell carcinoma

Indexed keywords

PROTEIN BCL 2;

ADULT; AGED; ANEUPLOIDY; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOIDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MALE; NEPHRECTOMY; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PLOIDIES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; S PHASE; SURVIVAL ANALYSIS;

EID: 23244448002     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2005.01081.x     Document Type: Article

References (28)

1. Srigley J, Hutter R, Gelb A et al. Current prognostic factors-renal cell carcinoma. Cancer 1997; 80: 994-6.
2. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990; 348: 334-8.
3. Tsujimoto Y, Jaffe E, Cossman J, Crosse CM. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985; 228: 1440-43.
4. Read JC. Bcl-2 Family proteins: role in dysfunction of apoptosis and chemoresistance in cancer. In: Martin SJ (ed.). Apoptosis and Cancer. Karger Landes Systems, Bazel, Switzerland, 1997; 64-97.
5. Hermine O, Haioun C, Lepage E et al. Prognostic significance of Bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 1996; 87: 265-72.
6. Fisher TC, Milner AE, Gregory CD et al. Bcl-2 modulation of apoptosis induced by anticancer drugs: resistance to thymidylate stress is independent of classical resistance pathways. Cancer Res. 1993; 53: 3321-6.
7. Di Silverio F, Casale P, Collela D et al. Independent value of tumour size and DNA ploidy for the prediction of disease progression in patients with organ-confined renal cell carcinoma. Cancer 2000; 88: 835-43.
8. Abou-Rebyeh H, Borgmann V, Nagel R, Al-Abadi H. DNA ploidy is a valuable predictor for prognosis of patients with resected renal cell carcinoma. Cancer 2001; 92: 2280-85.
9. Shameem IA, Shimabukuro T, Wada T, Kurisu H, Naito K. Expression of proliferating cell nuclear antigen and deoxyribonucleic acid value in renal cell carcinoma: correlation with different histopathological parameters and patient survival. Eur. Urol. 1996; 29: 78-84.
10. Tannapfel A, Hahn HA, Katalinic A et al. Prognostic value of ploidy and proliferation markers in renal cell carcinoma. Cancer 1996; 77: 164-71.
11. Aiello A, Delia D, Borrello MG et al. Flow cytometric detection of the mitochondrial bcl-2 protein in normal and neoplastic human lymphoid cells. Cytometry 1992; 13: 502-509.
12. Mickisch G, Carballido J, Hellsten S, Schulze H, Mensink H. Guidelines on renal cell cancer. Eur. Urol 2001; 40: 252-5.
13. McDonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bcl-2 in the prostate and its association to the emergence of androgen-independent prostate cancer. Cancer Res. 1992; 52: 6940-44.
14. Bauer JJ, Sesterhenn IA, Mostofi FK et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated localized prostate cancer patients. J. Urol. 1996; 155: 522A.
15. Huang A, Fone PD, Endwards RD. Immunohistochemical analysis of bcl-2 protein expression in renal cell carcinoma. J. Urol. 1999; 162: 610-613.
16. Lipponen P, Eskelinen M, Syrjanen K. Expression of tumor supression gene Rb, apoptosis supressing protein bcl-2 and c-myc have no independent prognostic value in renal adenocarcinoma. Br. J. Cancer 1995; 71: 863-7.
17. Takehiro S, Ikuo M. Expression of bcl-2, 53 oncoprotein, and proliferating cell nuclear antigen in renal cell carcinoma. Eur. Urol. 1999; 35: 242-8.
18. Paraf F, Gogusev J, Chretien Y, Droz D. Expression of bcl-2 oncoprotein in renal cell tumors. J. Pathol. 1995; 177: 247-52.
19. Hofmockel G, Wittmann A, Pammrich J, Bassukas ID. Expression of p53 and bcl-2 in primary locally confined renal cell carcinomas: no evidence for prognostic significance. Anticancer Res. 1996; 16: 3807-3811.
20. Vasavada SP, Novick AC, Williams BR. P53, bcl-2 and bax expression in renal cell carcinoma. Urology 1998; 51: 1057-1061.
21. Uchida T, Gao JP, Wang C et al. Clinical significance of p53, mdm2, and bcl-2 proteins in renal cell carcinoma. Urology 2002; 59: 615-20.
22. Kanamaru H, Li B, Miwa Y, Akino H, Okada K. Immunohistochemical expression of p53 and bcl-2 proteins is not associated with sarcomatoid change in renal cell carcinoma. Urol Res. 1999; 27: 169-73.
23. Gobe G, Rubin M, Williams G, Sawczuk I, Buttyan R. Apoptosis and expression of Bcl-2, Bcl-XL, and Bax in renal cell carcinomas. Cancer Invest. 2002; 20: 324-32.
24. Lee C, Genega E, Hutchinson B et al. Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high risk primary tumours. Urol. Oncol. 2003; 21: 179-84.
25. Ljungberg B, Roos G, Stenling R. Deoxyribonucleic axid content in metastatic renal cell carcinoma: clinical implications. Semin. Surg. Oncol. 1998; 4: 165-8.
26. Pepe S, Ruggiero A, D'Acquisto M et al. Nuclear DNA content-derived parameters correlated with heterogeneous expression of p53 and bcl-2 proteins in clear cell renal carcinomas. Cancer 2000; 89: 1065-1075.
27. Ljungberg B, Mehle C, Stenling R, Roos G. Heterogeneity in renal cell carcinoma and its impact on prognosis - a flow cytometric study. Br. J. Cancer 1996; 74: 123-7.
28. Ruiz-Cerda JL, Hernadez M, Sempere A et al. Intratumoural heterogeneity of DNA content in renal cell carcinoma and its prognostic significance. Cancer 1999 15; 86: 664-71.